Kidney cleanse? experimental drug aims to flush cholesterol from damaged kidneys

NCT ID NCT06489340

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial planned to test an experimental drug called VAR200 (2-HPβCD) in adults with type 2 diabetes and kidney disease. The drug works by removing extra cholesterol from kidney cells, which might help protect the kidneys. However, the study was withdrawn before any participants were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

2-hydroxypropyl-β-cyclodextrin (2-HPβCD)

What this could lead to

If it worked, this could point toward a new way to slow kidney damage in people with type 2 diabetes.

What could go wrong

The trial was withdrawn before enrolling anyone, so no results exist. It is very early-stage and may not be safe or effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinical Advancement Center, PLLC

    San Antonio, Texas, 78212, United States